

## Nirsevimab Documentation in the WAIS

Nirsevimab (Beyfortus) is a long-lasting monoclonal antibody injection for protection against Respiratory Syncytial Virus (RSV). Click [here](#) for more information about RSV and Nirsevimab.

Nirsevimab is offered through the Washington State [Childhood Vaccine Program](#). Orders, inventory management, and patient immunization documentation should be completed in the Washington Immunization Information System (WAIS) for Nirsevimab supplied through the [CVP](#).

Codes and Crosswalks for Fall 2023 RSV vaccines and monoclonal antibody products can be found [here](#).

### How do I document Nirsevimab injections?

Nirsevimab injections can be recorded directly into the WAIS. If your EHR system exchanges data with the WAIS, you can document Nirsevimab administrations in your EHR to submit the data to the WAIS.

The WAIS and most EHR systems are designed to deduplicate records entered for the same patient on the same day. Some patients may receive two injections of Nirsevimab at the same time in different anatomical sites. Starting January 2024, the WAIS will accept records of two doses of Nirsevimab entered on the same day for the same patient (up to 20 months of age).

**ATTENTION: In February 2024, an issue was found in the WAIS regarding the ability to report two doses of Nirsevimab given to the same patient on the same day. The system cannot currently accept two records of Nirsevimab entered for the same patient on the same day. Our IIS third party vendor is addressing the problem, and a resolution should be implemented soon. We apologize for any inconvenience or confusion.**



**Questions?** Contact the IIS Help Desk at 1-800-325-5599 or [WAISHelpDesk@doh.wa.gov](mailto:WAISHelpDesk@doh.wa.gov)

#### *EHR documentation submitted to the WAIS via HL7 interface*

- Record and submit electronic immunization messages to the WAIS from your EHR as you do for other vaccines. Two doses of Nirsevimab given to the same patient on the same day will be accepted by the WAIS without deduplication for infants up to 20 months old.
- If your EHR system deduplicates two doses of Nirsevimab administered on the same day, you will not be able to send both doses electronically and may need to manually enter the second dose directly into the WAIS.

## Nirsevimab Documentation in the WAIS

### Direct data entry in the WAIS

- Click [here](#) for more about documenting immunization records directly in the WAIS. You can record a second dose on the same day for the same patient (up to 20 months old).

**Vaccination View/Add**

**Special considerations on record for patient, please review notes below.**

**The patient was reported to have had the Chickenpox disease.**

(\* - Historicals , # - Adverse Reaction , !1 - Warning , !2 - Warning , !3 - Warning , ^ - Compromised)

Documented By:

Double-click in any date field below to enter the default date:

Vaccine	1	2	3
RSV, mAb, nirsevimab-alip, 1.0 mL, neonate to 24 months (Beyfortus)	12/27/2023	12/27/2023	<input type="text"/>

### How do I manage Nirsevimab inventory in the WAIS?

Doses of Nirsevimab provided through the Childhood Vaccine Program will be added to your WAIS inventory when you electronically receive your clinic's order. Click [here](#) for more information about ordering and receiving in the WAIS.

Click [here](#) to learn about manually adding products into your clinic's WAIS inventory, and for guidance on reconciling and reporting inventory.

If you are submitting Nirsevimab immunization records from your EHR to the WAIS, only one dose will subtract from your clinic's WAIS inventory if you report a 'double' dose. Report two separate immunization events for two doses to decrement from your WAIS inventory. Dose volume does not affect inventory quantity in the WAIS.

[Inventory Reconciliation](#) should be completed frequently in the WAIS to ensure accurate counts. The [Lot Usage and Recall Report](#) and the [Patient Detail Report](#) are helpful IIS tools to assist with troubleshooting inventory discrepancies.

### What else should I know about documenting Nirsevimab in the WAIS?

Patient weight data is not supported or accepted by the WAIS. Because weight information is not recorded, the WAIS will not detect when an invalid dose is administered.

There is currently no forecasting for Nirsevimab in the WAIS - refer to current ACIP recommendations.

Click [here](#) for guidance on searching for or advertising Nirsevimab available for transfer between healthcare facilities.